LAVA Therapeutics N.V.
LVTX
$1.28
$0.043.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 67.71% | -48.20% | -1,400.18% | 91.35% | 27.63% |
| Total Depreciation and Amortization | -203.77% | -7.02% | -7.69% | 178.66% | -198.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -146.91% | 1,274.32% | 23.11% | -111.70% | 1,187.70% |
| Change in Net Operating Assets | 190.87% | 1,080.45% | 77.11% | 91.82% | -544.37% |
| Cash from Operations | 83.72% | -2.93% | -645.24% | 90.45% | -65.70% |
| Capital Expenditure | 100.00% | -- | -- | -- | 83.33% |
| Sale of Property, Plant, and Equipment | -400.00% | -33.33% | -96.63% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,245.51% | 39.29% | -46.58% | 107.24% | 48.42% |
| Cash from Investing | 2,354.36% | 31.86% | -52.79% | 108.26% | 48.44% |
| Total Debt Issued | -- | -300.78% | -0.77% | -- | -- |
| Total Debt Repaid | -85.59% | 21.28% | -2.17% | -118.75% | 397.98% |
| Issuance of Common Stock | -100.00% | -88.24% | 112.50% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 44.02% | -7,460.00% | -- | -100.00% | 252.70% |
| Foreign Exchange rate Adjustments | -405.61% | 801.64% | 90.42% | -149.15% | 356.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 199.13% | -0.27% | -675.96% | 94.34% | 26.11% |